Table 3.
Multivariable analyses for the subpopulation with TTR ≤6 months
| Variables | HR | Inferior 95% CI | Superior 95% CI | P |
|---|---|---|---|---|
| Progression-free survival | ||||
| Cohort (T-DM1 versus P + T + taxane) | 2.89 | 1.31 | 6.39 | 0.009 |
| Age at first-line start (continuous) | 0.99 | 0.95 | 1.04 | 0.778 |
| Hormone receptor status (positive versus negative) | 1.85 | 0.76 | 4.52 | 0.175 |
| (Neo)adjuvant CT (yes versus no) | 1.17 | 0.18 | 7.45 | 0.867 |
| (Neo)adjuvant trastuzumab (yes versus no) | 1.25 | 0.26 | 5.86 | 0.782 |
| Visceral (liver/lung) metastases ab initio (yes versus no) | 2.40 | 1.05 | 5.46 | 0.038 |
| Brain metastases ab initio (yes versus no) | 3.24 | 1.20 | 8.76 | 0.021 |
| Overall survival | ||||
| Cohort (T-DM1 versus P + T + taxane) | 3.80 | 1.11 | 13.06 | 0.034 |
| Age at first-line start (continuous) | 0.98 | 0.92 | 1.04 | 0.506 |
| Hormone receptor status (positive versus negative) | 1.95 | 0.54 | 7.03 | 0.306 |
| (Neo)adjuvant CT (yes versus no) | 1.22 | 0.10 | 15.22 | 0.876 |
| (Neo)adjuvant trastuzumab (yes versus no) | 0.60 | 0.06 | 5.62 | 0.652 |
| Visceral (liver/lung) metastases ab initio (yes versus no) | 2.93 | 0.95 | 9.04 | 0.062 |
| Brain metastases ab initio (yes versus no) | 2.47 | 0.54 | 11.22 | 0.242 |
CI, confidence interval; CT, chemotherapy; HR, hazard ratio; P + T, pertuzumab + trastuzumab; TTR, time-to-relapse.
Bold values indicate significant P values.